Last reviewed 2026-04-19 · How we verify

Blastic phase chronic myeloid leukemia

Approved treatments

• Gleevec · M.D. Anderson Cancer Center
• Sprycel · Handa Therap
  Sprycel works by blocking the activity of a specific protein called Ephrin type-B receptor 6, which is involved in the growth and survival of cancer cells.
• Bosulif · Pfizer
  Bosulif blocks the abnormal tyrosine kinase activity in cancer cells, inhibiting their growth and proliferation.
• Gleevec · Novartis
  Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation.
• Bosulif · Pfizer
  Bosulif works by blocking the activity of a specific enzyme called tyrosine-protein kinase ABL1, which is involved in the growth and survival of cancer cells.

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Blastic phase chronic myeloid leukemia patent landscape — cliff calendar, originator estates, attackable patents
• Blastic phase chronic myeloid leukemia treatment landscape brief
• Blastic phase chronic myeloid leukemia treatment updates RSS

Frequently asked questions about Blastic phase chronic myeloid leukemia

Related

• Treatment landscape: Blastic phase chronic myeloid leukemia patent cliff · Blastic phase chronic myeloid leukemia CI report
• Treatment: Gleevec · M.D. Anderson Cancer Center
• Treatment: Sprycel · Handa Therap
• Treatment: Bosulif · Pfizer
• Treatment: Gleevec · Novartis
• Treatment: Bosulif · Pfizer
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing